The approved medication ruxolitinib dampens inflammatory responses to malaria and can enhance immune memory to the parasite in infected volunteers, supporting its potential as an adjunctive therapy to improve outcomes. #ScienceTranslationalMedicine https://scim.ag/44tu6TB

This week's issue of #ScienceTranslationalMedicine has arrived! A transcriptional signature could inform smarter antibiotic use in newborns with sepsis, an approved medication boosts anti-malaria immunity in volunteers, and more. https://scim.ag/43PsmE6

So pleased to share our study of a host-directed therapy to boost malaria immunity. Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum | Science Translational Medicine www.science.org/doi/10.1126/...

Excited to have our latest research published in @jem.org this week and also highlighted by @natrevimmunol.nature.com @wehi-research.bsky.social @benjbroom.bsky.social